Legislative History of the Drug Price Competition and Patent Term Restoration Act of 1984 - PL 98-417

An act to amend the Federal Food, Drug, and Cosmetic Act to revise the procedures for new drug applications, to amend title 35, United States Code, to authorize the extension of the patents for certain regulated products, and for other purposes.

Although the Federal Food, Drug, and Cosmetic Act made it possible for generic companies to get regulatory approval for drugs by filing an Abbreviated New Drug Application (ANDA), in the early 1980s it became clear that very few generics were coming to market. Congress studied the issue and realized that under patent and regulatory law, it was easy for innovator companies to make it difficult for generic companies to successfully file ANDAs and that the regulatory pathway to get ANDAs approved was irregular and uncertain. In response, the Hatch-Waxman Act was negotiated and enacted.

Legislative History of the Drug Price Competition and Patent Term Restoration Act of 1984 - PL 98-417

 

 

Congressional Materials
(20 years of Congressional materials)
 
Congressional Hearings
 
 

 

 

<<--Return to Patent History Index